http://www.edisonpharma.com/ The Edison Pharmaceuticals Company Mon, 5 Jan 2009 21:41:33 -0800 Mon, 5 Jan 2009 21:41:33 -0800 Copyright 2007 http://www.edisonpharma.com/ editor@mysite.com webmaster@mysite.com en-us http://blogs.law.harvard.edu/tech/rss http://www.edisonpharma.com/common/images/header-h1.png http://www.edisonpharma.com/ Search on the Edison Pharmaceuticals keyword http://www.edisonpharma.com/home/search/ Chats with Guys

Edison is beyond excited in our programs and it's not because we have great science, in fact we do, but it goes beyond that. There has been remarkable research done about the first chemical template that we're bringing forward, which is based on Coenzyme Q10 , which is central to the function of the mitochondria. There is a wealth of data suggesting that this molecular template has utility for diseases involving the mitochondria ranging from the classic respiratory chain diseases and on to diseases such as Huntington's, Parkinson's, and Alzheimer's. We here at Edison look at that as footprints in the sand. They are the inspirational remnants of fantastic observations which have been made by clinicians and basic scientists. Here at Edison we're focused three discrete questions around these wonderful observations. First, can we design a CoQ10 that overcomes the obstacle of being absorbed by the body? Secondly, can we improve the intrinsic activity of this compound by altering the redox nucleus? And third, can we build into the molecule certain features that will allow it to cross the blood brain barrier with alacrity. These three components, absorption, efficacy and blood brain barrier crossing, we think are our core competency with regard to Coenzyme Q10 and improving upon it and really building upon these wonderful footprints in the sand.]]> http://www.edisonpharma.com/company/videos/page/chats/videosid/69/ Guy Miller Sun, 28 Oct 2012 10:02:41 -0700 Chats with Guys

We are working very, very closely with patients and their primary care providers to develop a company that we think is unique on two points. The first point is truly connecting with these patient families is more than just supporting them, it's truly understanding the natural course of these diseases- what these patients face; and being able to further characterize and dissect apart the understandings of these diseases. That's crucial to us because it not only allows us to develop therapies for this very needy group of people who absolutely must have drugs developed for them, but it allows us to take those learnings and parley them to other diseases that today, we believe have their roots in disturbances in energy metabolism.]]> http://www.edisonpharma.com/company/videos/page/chats/videosid/68/ Guy Miller Sun, 28 Oct 2012 10:02:31 -0700 Chats with Guys

We're very grateful at Edison for the support we have received from foundations and government granting agencies. Edison to date has received over 4 peer reviewed grants which have significantly enabled our programs. These have come from various rare disease foundations and the US National Institutes of Health, which have expedited our first drug into clinical development. ]]> http://www.edisonpharma.com/company/videos/page/chats/videosid/67/ Guy Miller Sun, 28 Oct 2012 10:02:22 -0700 Chats with Guys

Foundations today are not what they used to be. Foundations of old were aggregators of capital. And then they would distribute that capital to various scientists or clinicians, hoping that a cure would ultimately come back to them. Today, foundations are taking a much more active role, in steering their money into a cure. They're bringing onboard critical resources that are driving innovation in both the science, technology and clinical translation side.]]> http://www.edisonpharma.com/company/videos/page/chats/videosid/66/ Guy Miller Sun, 28 Oct 2012 10:02:12 -0700 Chats with Guys

The chairman of our science advisory board, Professor Sidney Hecht, was also my PhD dissertation advisor and one night, late in the lab, he came forward after writing a review of some manuscripts, and we were talking about the philosophy of science and he told me, "Guy, you know you will have arrived as a scientist when you finally relinquish control and understand that when a big problem crawls under your skin, it owns you, you don't own it." Energy metabolism drives us, it drives me. I want to undestand, how nature is designed in terms of its energy blueprint. But I want to do that past just understanding that blueprint, I want to understand that blueprint as to how it positively will impact children, and other people with diseases that impact energy metabolism. ]]> http://www.edisonpharma.com/company/videos/page/chats/videosid/65/ Guy Miller Sun, 28 Oct 2012 10:02:02 -0700 Chats with Guys

This is a really exciting time for Edison Pharmaceuticals in that our first molecule is heading into the clinic. Our first compound, A0001 is heading into clinical development in Q2, 2008, and behind that are several more compounds that we expect to be nominating a lead and ultimately a clinical candidate from by the end of Q4, 2008.]]> http://www.edisonpharma.com/company/videos/page/chats/videosid/64/ Guy Miller Sun, 28 Oct 2012 10:01:50 -0700